Vermillion, Inc. is engaged in the discovery, development and commercialization of diagnostic and bio-analytical solutions that help physicians diagnose, treat and improve outcomes for women. The Company’s lead product, OVA1, is a blood test designed to identify women who are at high risk of having a malignant ovarian tumor prior to surgery. The Company’s tests are intended to detect, characterize and stage disease, and to help guide decisions regarding patient treatment, which include decisions to refer patients to specialists, to perform additional testing, or to assist in monitoring response to therapy. The Company concentrates its development of for gynecologic disease, with an initial focus on ovarian cancer. It also address clinical questions related to early disease detection, treatment response, monitoring of disease progression, and prognosis and others through collaborations with academic and clinical research institutions.
